Clinical Trials
12 trialsNCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT04993677 2025-05-11
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
Phase 2 Completed
NCT03052127 2024-02-01
Study in Subjects With Small Primary Choroidal Melanoma
Aura Biosciences
Phase 1/2 Completed
NCT02743611 2023-10-05
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT02570308 2023-03-21
A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
Immunocore Ltd
Phase 1/2 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT00084656 2022-04-14
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT02771340 2020-10-01
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Iconic Therapeutics, Inc.
Phase 1 Completed
NCT01801358 2020-09-16
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Array BioPharma
Phase 1/2 Terminated
NCT02889861 2020-07-27
IMCgp100-401 Rollover Study
Immunocore Ltd
Phase 2 Terminated
NCT01974752 2017-01-05
SUMIT
AstraZeneca
Phase 3 Completed